Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Effect of Tianshengyuan-1 (TSY-1) on telomerase activity and hematopoietic recovery - in vitro, ex vivo, and in vivo studies.

Lu S, Qin X, Yuan S, Li Y, Wang L, Jin Y, Zeng G, Yen L, Hu J, Dang T, Song S, Hou Q, Rao J.

Int J Clin Exp Med. 2014 Mar 15;7(3):597-606. eCollection 2014.

2.

Tianshengyuan-1 (TSY-1) regulates cellular Telomerase activity by methylation of TERT promoter.

Yu W, Qin X, Jin Y, Li Y, Santiskulvong C, Vu V, Zeng G, Zhang Z, Chow M, Rao J.

Oncotarget. 2017 Jan 31;8(5):7977-7988. doi: 10.18632/oncotarget.13939.

3.

Telomerase gene therapy rescues telomere length, bone marrow aplasia, and survival in mice with aplastic anemia.

Bär C, Povedano JM, Serrano R, Benitez-Buelga C, Popkes M, Formentini I, Bobadilla M, Bosch F, Blasco MA.

Blood. 2016 Apr 7;127(14):1770-9. doi: 10.1182/blood-2015-08-667485. Epub 2016 Feb 22.

4.

Telomerase activity and telomere length in acute and chronic leukemia, pre- and post-ex vivo culture.

Engelhardt M, Mackenzie K, Drullinsky P, Silver RT, Moore MA.

Cancer Res. 2000 Feb 1;60(3):610-7.

5.

Special Education: Aplastic Anemia.

Teramura M, Mizoguchi H.

Oncologist. 1996;1(3):187-189.

6.

Defective telomere elongation and hematopoiesis from telomerase-mutant aplastic anemia iPSCs.

Winkler T, Hong SG, Decker JE, Morgan MJ, Wu C, Hughes WM 5th, Yang Y, Wangsa D, Padilla-Nash HM, Ried T, Young NS, Dunbar CE, Calado RT.

J Clin Invest. 2013 May;123(5):1952-63. doi: 10.1172/JCI67146. Epub 2013 Apr 15.

7.

Reversibility of Defective Hematopoiesis Caused by Telomere Shortening in Telomerase Knockout Mice.

Raval A, Behbehani GK, Nguyen le XT, Thomas D, Kusler B, Garbuzov A, Ramunas J, Holbrook C, Park CY, Blau H, Nolan GP, Artandi SE, Mitchell BS.

PLoS One. 2015 Jul 2;10(7):e0131722. doi: 10.1371/journal.pone.0131722. eCollection 2015.

8.

Physician Education: Myelodysplastic Syndrome.

Yoshida Y.

Oncologist. 1996;1(4):284-287.

9.

Telomere length variation and telomerase activity expression in patients with congenital and acquired aplastic anemia.

Polychronopoulou S, Koutroumba P.

Acta Haematol. 2004;111(3):125-31. Review.

PMID:
15034232
10.

Granulocyte colony-stimulating factor administration upregulates telomerase activity in CD34+ haematopoietic cells and may prevent telomere attrition after chemotherapy.

Szyper-Kravitz M, Uziel O, Shapiro H, Radnay J, Katz T, Rowe JM, Lishner M, Lahav M.

Br J Haematol. 2003 Jan;120(2):329-36.

PMID:
12542495
11.

Telomerase activity in myelodysplastic syndromes.

Gürkan E, Tanriverdi K, Başlamişli F.

Leuk Res. 2005 Oct;29(10):1131-9. Epub 2005 Apr 7.

PMID:
16111531
12.

Telomere maintenance and human bone marrow failure.

Calado RT, Young NS.

Blood. 2008 May 1;111(9):4446-55. doi: 10.1182/blood-2007-08-019729. Epub 2008 Jan 31. Review.

13.

Telomerase regulation, cell cycle, and telomere stability in primitive hematopoietic cells.

Engelhardt M, Kumar R, Albanell J, Pettengell R, Han W, Moore MA.

Blood. 1997 Jul 1;90(1):182-93.

14.

Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia.

Yamaguchi H, Calado RT, Ly H, Kajigaya S, Baerlocher GM, Chanock SJ, Lansdorp PM, Young NS.

N Engl J Med. 2005 Apr 7;352(14):1413-24.

15.

Telomere dysfunction and hematologic disorders.

Paiva RM, Calado RT.

Prog Mol Biol Transl Sci. 2014;125:133-57. doi: 10.1016/B978-0-12-397898-1.00006-2. Review.

PMID:
24993701
16.

Measurement of secondary colony formation after 5 weeks in long-term cultures in patients with myelodysplastic syndrome.

Sato T, Kim S, Selleri C, Young NS, Maciejewski JP.

Leukemia. 1998 Aug;12(8):1187-94.

PMID:
9697872
17.

Telomere elongation and clinical response to androgen treatment in a patient with aplastic anemia and a heterozygous hTERT gene mutation.

Ziegler P, Schrezenmeier H, Akkad J, Brassat U, Vankann L, Panse J, Wilop S, Balabanov S, Schwarz K, Martens UM, Brümmendorf TH.

Ann Hematol. 2012 Jul;91(7):1115-20. doi: 10.1007/s00277-012-1454-x. Epub 2012 Apr 4.

PMID:
22476886
18.

[The relationship of telomere and telomerase activity with outcome of aplastic anemia after immunosuppressive therapy].

Song JY, Kuang LP, Wang Y, Li YH, Wu JL, Zhang H, Li L, Wang YC, Jiang ZJ, Xiao Y.

Zhonghua Xue Ye Xue Za Zhi. 2013 Sep;34(9):771-6. doi: 10.3760/cma.j.issn.0253-2727.2013.09.008. Chinese.

PMID:
24103875
19.

Identification and functional characterization of novel telomerase variant alleles in Japanese patients with bone-marrow failure syndromes.

Takeuchi J, Ly H, Yamaguchi H, Carroll KA, Kosaka F, Sawaguchi K, Mitamura Y, Watanabe A, Gomi S, Inokuchi K, Dan K.

Blood Cells Mol Dis. 2008 Mar-Apr;40(2):185-91. Epub 2007 Oct 23.

20.

In vitro and in vivo evidence for the long-term multilineage (myeloid, B, NK, and T) reconstitution capacity of ex vivo expanded human CD34(+) cord blood cells.

Kobari L, Pflumio F, Giarratana M, Li X, Titeux M, Izac B, Leteurtre F, Coulombel L, Douay L.

Exp Hematol. 2000 Dec;28(12):1470-80.

PMID:
11146169

Supplemental Content

Support Center